UnknownPHASE1, PHASE2NCT04253132

Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks

Studying Classic progressive supranuclear palsy syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NeuroTau, Inc.
Principal Investigator
Nasser Zawia, PhD
NeuroTau, Inc.
Intervention
Tolfenamic Acid(drug)
Enrollment
24 enrolled
Eligibility
40-85 years · All sexes
Timeline
20212022

Study locations (1)

Collaborators

The Cleveland Clinic

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04253132 on ClinicalTrials.gov

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Classic progressive supranuclear palsy syndrome

← Back to all trials